达雷妥尤单抗在中国单中心儿童慢性难治性免疫性血小板减少症中的早期快速应答
本文报告3例儿童慢性难治性原发免疫性血小板减少症(CRITP)患者(2男1女,年龄12、5、7岁),接受达雷妥尤单抗联合阿伐曲泊帕治疗,随访超过25周。3例均获得早期应答和完全应答,出血评分从3级降至0级,未见显著治疗相关不良事件。作者认为该联合方案可能安全有效,但需进一步探索。
要点
- 3例CRITP患儿接受达雷妥尤单抗联合阿伐曲泊帕,均在Day 45内获得应答。
- 3例均达到完全应答,持续应答时间分别为48、175、204天。
- 随访期间出血评分从3级降至0级,未见显著治疗相关不良事件。
核心结论
- 达雷妥尤单抗联合阿伐曲泊帕可能为儿童CRITP的安全有效治疗,但需进一步探索。
研究设计与样本
- 本文报告本中心3例儿童CRITP患者(2男1女,年龄12、5、7岁)接受达雷妥尤单抗联合阿伐曲泊帕治疗,随访超过25周。
主要发现
- 治疗前免疫性血小板减少症病程分别为9、1.4、4年,基线血小板计数分别为4、6、9×10^9/L,出血评分均高于2级,既往用药数>3种。
- 达雷妥尤单抗应答时间(血小板≥30×10^9/L且较基线至少翻倍)分别为Day 45、Day 6、Day 4,完全应答(血小板≥100×10^9/L)分别为Day 51、Day 6、Day 8。
- 持续应答(随访终点时血小板>30×10^9/L且≥75%的血小板计数评估达标)分别为48、175、204天,随访时间分别为39.1、25.9、29.7周。
- 随访期间出血评分从3级降至0级,未见显著治疗相关不良事件。
临床怎么用
- 作者认为达雷妥尤单抗联合阿伐曲泊帕可能为儿童CRITP的安全有效治疗,但需进一步探索。
局限性
- 原文指出该联合治疗需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic refractory primary immune thrombocytopenia (CRITP) is currently defined as refractory to multiple therapeutic of second-line agents with or without splenectomy, faced with the threat of severe bleeding and challenging to obtain effective treatment. Although stable and effective drug therapy is needed, it is tough to find one. Daratumumab (Dara), an anti-CD38 monoclonal antibody presented the target cloned plasma cells in multiple myeloma, has also been reported to be effective in refractory autoimmune cytopenia in some case or series reports and ongoing clinical trials for adult patients with CRITP. Here, we report the early and durable response of Dara combination with avatrombopag in three CRITP patients (2 male and 1 female aged 12, 5 and 7 years, respectively) in our centre, with a follow-up period of more than 25 weeks. Before Dara, the duration of immune thrombocytopenia was 9, 1.4 and 4 years, respectively, a baseline platelet count of 4, 6, 9 × 109/L, the bleeding score was all above level 2 and the number of previous drugs was >3. The time to response (R: Plt ≥30 × 109/L with at least a twofold increase in the baseline count) of Dara was on Day 45, 6 and 4 and achieved complete response (CR: Plt ≥100 × 109/L) on Day 51, 6 and 8, the sustained response (SR: Plt >30 × 109/L following Dara at ≥75% of the platelet count assessment at follow-up end-point since the patient achieved response) was 48, 175 and 204 days with the follow-up time of 39.1, 25.9 and 29.7 weeks. The bleeding score decreased from grade 3 to grade 0 during follow-up. No significant treatment-related adverse events were found during follow-up. Dara combination with avatrombopag may be a safe and efficacious therapy for children with CRITP, but it needs to be further explored.
引用
- Hu Y, Wang Z, Ma J, et al. The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China. Br J Haematol. 2024. PMID: 38831655. doi:10.1111/bjh.19553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。